No registrations found.
ID
Source
Brief title
Health condition
Insulin resistance, Type 2 diabetes mellitus
Sponsors and support
•TNO Quality of Life, Zeist, NL
•HZPC Holland BV, Metslawier, NL
•Cosun Food Technology Centre, Roosendaal, NL
•University Medical Center Groningen, Groningen, NL
Project leader:
Dr. Hans van Doorn
HZPC Holland BV
Roptawei 4
9123 JB Metslawier
The Netherlands
Intervention
Outcome measures
Primary outcome
The main parameters of this study are the rate of appearance of exogenous glucose in plasma (glucose kinetics) as well as the quantity of fermentation products.
Glucose kinetics is calculated using total plasma glucose concentration, the 13C/12C-ratio of glucose in plasma samples, and the 2H/1H-glucose ratio in plasma samples.
Parameters of fermentation measured are hydrogen in breath, 13CO2 in breath, short chain fatty acids in plasma and urine.
Secondary outcome
The secondary study parameters are plasma concentrations of total blood glucose, insulin, incretins and markers of inflammation. Sensation of appetite and satiety (VAS registration) as well as feeling and extent of discomfort after consumption of the test meal are also considered as secondary parameters. Other study parameters include body weight, BMI, family history of T2DM, habitual diet, smoking habits and sportive activities.
Background summary
Consumption of potato products with a higher amylose/amylopectin ratio is expected to result in increased colonic fermentation as well as in lower postprandial glucose and insulin concentrations compared to the consumption of conventional potato products. This will be investigated in young, healthy men using the dual isotope technique.
Study objective
Consumption of potato products with a higher amylose/amylopectin ratio is expected to result in increased colonic fermentation as well as in lower postprandial glucose and insulin concentrations compared to the consumption of conventional potato products.
A lower glycemic response is favourable for patients with Type 2 Diabetes Mellitus (T2DM) and might also decrease the risk of developing obesity and T2DM.
Primary Objective:
To investigate the differences in rate and extent of digestion as well as in colonic fermentation of HAM compared to that of CON (using the dual isotope technique).
Secondary Objectives:
To investigate what is the difference in glycemic and insulinemic response and the plasma concentrations of incretins and inflammation markers after consumption of HAM compared to CON.
Study design
Blood samples are drawn during the whole 15h study period (2x) via a venous catheter and several breath and urine samples will be collected.
Intervention
In this explorative intervention study two different test meals will be consumed, with at least one week between each test meal. In the test meals, which will be made from potato puree and starch, the ratio of amylose and amylopectin will differ. The high amylose test meal will have an amylose/amylopectin ratio of 50/50, whereas the conventional test meal will have an amylose/amylopectin ratio of 20/80 (which is the ratio in potatoes).
The volunteer will drink 250 mL of water with the test meal. The test meals are enriched with the stable isotope 13C and volunteers are infused with a tracer amount of the stable isotope 2H for 6 h. This method called the ¡®dual isotope technique¡¯ is used in order to calculate glucose kinetics.
Antonius Deusinglaan 1
M.G. Priebe
Building 3215 4th floor
Groningen 9713 AV
The Netherlands
+31 (0)50 3619386
m.g.priebe@med.umcg.nl
Antonius Deusinglaan 1
M.G. Priebe
Building 3215 4th floor
Groningen 9713 AV
The Netherlands
+31 (0)50 3619386
m.g.priebe@med.umcg.nl
Inclusion criteria
1. Healthy male volunteer aged ≥ 18;
2. Used to eat breakfast (solid food);
3. Not involved in intensive sportive activities more than twice a week (e.g. playing football, tennis, running, race-cycling, swimming);
4. Produces hydrogen after ingestion of fermentable carbohydrates;
5. Stable weight and no intention to loose weight until completion of the study.
Exclusion criteria
1. Diabetes mellitus;
2. Gastrointestinal disorders (including constipation);
3. BMI < 18 or > 25 kg/m2;
4. Not being able to fast overnight (12 hours);
5. Intake of medication (from 2 weeks before screening until the end of the study, except for sporadic use of paracetamol and/or treating an AE);
6. Undergone digestive tract surgery (except appendectomy);
7. Intake of antibiotics in the three months before the study;
8. Intake of pre- or probiotics more than once per week;
9. Donation of blood (> 500 mL) within the last 3 months prior to admission to the clinic;
10. Inflammatory disease (possibly interfering with measurement of parameters in this study);
11. Participation to another clinical study within 90 days before enrolment;
12. Positive drug screen or alcohol breath test at day before study.
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL2491 |
| NTR-old | NTR2608 |
| CCMO | NL31397.056.10 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| OMON | NL-OMON35079 |